| Name | Title | Contact Details |
|---|---|---|
Chris Adams |
Founder and Chief Executive Officer | Profile |
Rapid Micro Biosystems accelerates the detection of microbial contamination in the manufacture of pharmaceuticals, biologics, medical devices, and personal care products. The company`s Growth Direct™ Platform—the first and only growth-based platform to fully automate traditional microbial testing—detects contamination more quickly, delivering compelling economic benefits while improving quality control processes. The Growth Direct platform replaces slow, error-prone, manual processes, allowing manufacturers to accelerate timelines, maximize capacity, and reduce operational risk and downtime, all while maintaining the highest standards of data integrity. Rapid Micro Biosystems is dedicated to providing groundbreaking technology and products to support biomanufacturing companies in their mission to deliver the highest possible quality products for improved patient outcomes. Rapid Micro Biosystems is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Germany and the Netherlands.
Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective.
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.